Julia Gaebler, PhD
VP of Commercial Strategy and Portfolio Planning
Dr. Gaebler joined Milestone as VP, Strategy and Portfolio Planning in March 2021. She brings more than 25 years of experience in the biopharmaceutical industry, in commercial strategy, global market access, pricing, and health policy.
Prior to joining Milestone, Dr. Gaebler was Partner at Health Advances, a life sciences strategy consulting firm, where she focused on asset monetization, corporate development, and commercial opportunity assessment for early to mid-size biopharma, digital health, medtech, and data platform companies. Before Health Advances, at Biogen, Dr. Gaebler was responsible for the Global Market Access launches of Tecfidera, disease-modifying therapy for MS, and Fampyra, a first-in-class treatment for walking mobility for MS. She has also held various positions in medical affairs, commercial operations, R&D, pricing, and health policy at Amylin Pharmaceuticals, Hoffmann-La Roche, Roche Labs, and the RAND Corporation.
In addition to her industry track record, Dr. Gaebler has held Adjunct positions at UCLA, UCSD Division of Global Public Health and the RAND Pardee Graduate School. She has published 65+ articles on health technology assessment, health policy, and economics across biopharma, medtech, diagnostics, and public health in journals such as Nature, Journal of Pediatrics, and Journal of Vascular Surgery, among others.
Julia received a PhD in Decision Analysis and Health Policy from Harvard University, an MA in International Economics from Johns Hopkins University, and a BA from the University of Pennsylvania.